Previously, Mr. Hibben served as a senior executive and a corporate and business development consultant for public and private biopharmaceutical companies, including, among others: Centagenetix, Inc., in conjunction with its merger into Elixir Pharmaceuticals, Inc.; Pericor Science, Inc., where he led strategic planning, business operations, and product development for this start-up advancing a novel epithelial drug-delivery technology; and Ontogeny, Inc. (now Curis, Inc.), where he guided Ontogeny's merger with Reprogenesis and Creative Biomolecules. Mr. Hibben has an MBA from
About Cequent Pharmaceuticals, Inc. (www.cequentpharma.com)
An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human disorders - from inflammatory disease to cancer - based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/
|SOURCE Cequent Pharmaceuticals|
Copyright©2009 PR Newswire.
All rights reserved